One of the earliest studies to assess quality of life in patients with PBC included 276 British patients, mostly women, who had worse scores on overall quality of life compared with controls (P<0. ...

Medically reviewed by Jay N. Yepuri, MD Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the ...

Sclerosing cholangitis and primary biliary cirrhosis, which is now called primary biliary cholangitis (PBC), are chronic cholestatic liver diseases, but they differ in their causes, affected bile ...

Lowrey writes about living with PBC in the Atlantic article, "Why People Itch and How to Stop It."She says a big part of her struggle is coming to terms with the fact that she may never feel fully ...

With the FDA approval of Livdelzi, people with PBC have good reason to be excited about future treatment options available to them. Livdelzi is a drug now proven to be effective at improving both ...

- 28-week data from the Phase 2b VANTAGE PBC study highlights statistically significant improvements in pruritus and numeric improvements in fatigue, the two most burdensome symptoms of PBC ...

The most common adverse reactions with Livdelzi were headache, abdominal pain, nausea, abdominal distension, and dizziness. The company noted that the FDA granted accelerated approval for Livdelzi ...

LONDON - GSK plc (LSE/NYSE:LON: GSK) has announced successful results from the GLISTEN phase III trial for linerixibat, a treatment aimed at relieving cholestatic pruritus in patients with primary ...

NORTHAMPTON, MA / ACCESS Newswire / May 15, 2025 / "Living with primary biliary cholangitis (PBC) can be an isolating experience," explains Dilek, a mother of two from Germany who suffers from the ...

With an FDA approval in hand for primary biliary cholangitis (PBC) treatment Livdelzi (seladelpar), Gilead Sciences enters arenas that are both new and old.. While the California drugmaker is ...

FOSTER CITY, Calif., May 09, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today presented new data from its Phase 2b VANTAGE study at the European Association for the Study of ...